#cervical cancer

Prompt detection treatment of precancerous lesions cut the likelihood of developing anal cancer by more than half.

A pilot program is assessing whether self-testing for the cancer-causing virus can reach women who otherwise might not get screened.

Long-awaited results from the ANCHOR study suggest screening to detect precancerous lesions should be part of routine care.

A majority people with oral and throat cancer tested positive for DNA from high-risk HPV types in their saliva.

Teens can receive the cancer-preventing HPV vaccine at the same time as their COVID-19 vaccine.

Women living with HIV in the United States have a greater likelihood of developing cervical cancer than HIV-negative women.

The vaccine protects against nine types of human papillomavirus, including those that cause cervical and anal cancer.

Study suggests HIV-positive women could start cervical cancer screening at age 21.

The early cancer is detected, the easier it is to treat.

However, other malignancies caused by human papillomavirus, including anal and oral cancers, are on the rise.

Compared with unvaccinated women, the risk among women vaccinated before age 17 dropped by almost 90%.

More widespread vaccination could reduce cervical, anal, oral and other cancers caused by human papillomavirus.

The vaccine is safe and effective against cancer-causing strains of HPV, and yet anti-vaccination misinformation campaigns have taken hold.

International ‘dream team’ to use new technologies and prevention approaches to help those at highest risk.

Half of adolescents remain unprotected against virus that causes anal, cervical and oral cancer.

Having both chlamydia and high-risk HPV16 dramatically increases the risk of anal precancer.